Intuitive Surgical price target raised to $550 from $420 at Leerink Leerink raised its price target for Intuitive Surgical shares to $550 citing positive feedback on the just-released Xi system. The firm, however, keeps a Market Perform rating on the stock citing the recent rally.
Intuitive Surgical initiated with a Neutral at Piper Jaffray Piper Jaffray analyst Matt O'Brien started shares of Intuitive Surgical with a Neutral rating and $505 price target. O'Brien calls the stock "simply too expensive" relative to expected sales and earnings, but admits Intuitive's robotic surgical technology will likely dominate the market in the coming years. Further, the analyst thinks the company's da Vinci Prostatectomy and da Vinci Hysterectomy procedures could contract amid new diagnostic tests and insurance pushback. The stock closed yesterday up $2.05 to $496.37.